In the ever-evolving field of diabetes management, incretin mimetics have emerged as a transformative therapeutic class. Among these, retaglutide, retatrutide, and trizepatide represent advanced additions to the https://leadkau860094.blogunteer.com/37897220/glp-1-receptor-agonists-retaglutide-retatrutide-and-trizepatide